OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL

January 10th 2022

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

January 10th 2022

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS

January 7th 2022

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.

Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

January 7th 2022

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Ciombor on Rechallenging With EGFR Inhibitors in RAS/RAF Wild-Type CRC

January 7th 2022

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

Dr. Khushman on Best Practices in the Management of GI Cancers

January 7th 2022

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML

January 7th 2022

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma

January 7th 2022

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.

Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

January 7th 2022

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Dr. Leslie on Axi-Cel Vs SOC in Relapsed/Refractory Large B-Cell Lymphoma

January 7th 2022

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL

January 6th 2022

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

Dr. Randall on Preventing Early Failures With Osseointegrated Endoprostheses in Bone Sarcomas

January 6th 2022

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

January 6th 2022

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Dr. Koehne on Axi-Cel Vs Tisa-Cel in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

January 5th 2022

Guenther Koehne, MD, PhD, discusses the real-life study of CAR T-cell agents axicabtagene ciloleucel vs tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Heyman on the Evolution of BTK Inhibitors in Relapsed/Refractory MCL

January 5th 2022

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Mark on ​Questions Regarding Sequencing in Multiple Myeloma

January 5th 2022

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

January 5th 2022

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer

January 5th 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Dr. Burger on Choosing Frontline Therapy in CLL

January 5th 2022

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

January 5th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

NEXT PAGE
PREVIOUS PAGE